Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors

Haemophilia

Volumn 14, Issue 5, 2008, Pages 898-902

  Abshire, Thomas ^a   Kenet, G ^b  

^a EMORY UNIVERSITY   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Haemophilia; Inhibitors; NovoSeven ; rFVIIa; Safety; Thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INCIDENCE; LICENSING; OFF LABEL DRUG USE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGISTER; REVIEW; SINGLE DRUG DOSE; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; VEIN THROMBOSIS;

ADOLESCENT; ADULT; CHILD; FACTOR IX; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOEMBOLISM; YOUNG ADULT;

EID: 51249103799     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01829.x     Document Type: Review

References (15)

1. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
2. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
3. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
4. Hay CRM. Thrombosis and recombinant factor VIIa. J Thromb Haemost 2004; 2: 1698-9.
5. Sallah S, Isaksen M, Seremetis S, Payne Rojkjaer L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - a rebuttal. J Thromb Haemost 2005; 3: 820-2.
6. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - reply to a rebuttal. J Thromb Haemost 2005; 3: 819.
7. Aledort LM. MedWatch: An important instrument for postlicensing surveillance. J Thromb Haemost 2006; 4: 1637.
8. Roberts HR. Recombinant factor VIIa: How safe is the stuff? Can J Anaesth 2005; 52: 8-11.
9. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G; NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated FVII in patients with haemophilia and inhibitors. Thromb Haemost 2006; 95: 600-5.
10. Santagostino E, Manusco ME, Rocino A, Manusco G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
11. -1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008; 14: 287-94.
12. Parameswaran R, Shapiro AD, Gill JC, Kessler CM; HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
13. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
14. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
15. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK; NovoSeven in Surgery Study Investigators. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-32.